Log in
NASDAQ:PRPH

ProPhase Labs Stock Forecast, Price & News

$7.24
+0.22 (+3.13 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$6.60
Now: $7.24▼
$7.24
50-Day Range
$2.83
MA: $5.22▼
$8.93
52-Week Range
$1.20
Now: $7.24▼
$11.18
Volume79,327 shs
Average Volume100,936 shs
Market Capitalization$84.01 million
P/E RatioN/A
Dividend YieldN/A
Beta0.27
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ a supplement to support prostate and urinary health. In addition, the company provides contract manufacturing services for OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.44 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRPH
Previous Symbol
CUSIPN/A
CIK868278
Webwww.prophaselabs.com
Phone215-345-0919
Employees48

Debt

Debt-to-Equity RatioN/A
Current Ratio7.34
Quick Ratio5.87

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$9.88 million
Price / Sales8.50
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.97 per share
Price / Book7.46

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-3,150,000.00
Net Margins-14.31%
Return on Equity-13.52%
Return on Assets-12.23%

Miscellaneous

Outstanding Shares11,604,000
Market Cap$84.01 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$7.24
+0.22 (+3.13 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRPH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











ProPhase Labs (NASDAQ:PRPH) Frequently Asked Questions

How has ProPhase Labs' stock been impacted by COVID-19 (Coronavirus)?

ProPhase Labs' stock was trading at $2.0301 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRPH shares have increased by 256.6% and is now trading at $7.24.
View which stocks have been most impacted by COVID-19.

When is ProPhase Labs' next earnings date?

ProPhase Labs is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for ProPhase Labs.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) posted its quarterly earnings data on Tuesday, August, 11th. The company reported $0.01 earnings per share for the quarter. The company earned $3.62 million during the quarter. ProPhase Labs had a negative net margin of 14.31% and a negative return on equity of 13.52%.
View ProPhase Labs' earnings history.

How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?

ProPhase Labs announced a dividend on Wednesday, November 20th. Shareholders of record on Tuesday, December 3rd will be paid a dividend of $0.25 per share on Thursday, December 12th. The ex-dividend date of this dividend is Monday, December 2nd.
View ProPhase Labs' dividend history.

Who are some of ProPhase Labs' key competitors?

Some companies that are related to ProPhase Labs include TherapeuticsMD (TXMD), Puma Biotechnology (PBYI), Cue Biopharma (CUE), Bicycle Therapeutics (BCYC), Orphazyme A/S (ORPH), BioDelivery Sciences International (BDSI), Kamada (KMDA), Akebia Therapeutics (AKBA), Selecta Biosciences (SELB), ANI Pharmaceuticals (ANIP), iBio (IBIO), RedHill Biopharma (RDHL), Kalvista Pharmaceuticals (KALV), Catalyst Pharmaceuticals (CPRX) and Concert Pharmaceuticals (CNCE).
View all competitors.

What other stocks do shareholders of ProPhase Labs own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH).

Who are ProPhase Labs' key executives?

ProPhase Labs' management team includes the following people:
  • Mr. Ted William Karkus, Chairman & CEO (Age 61, Pay $249k)
  • Ms. Monica Brady, Chief Financial Officer (Age 43, Pay $187.56k)

What is ProPhase Labs' stock symbol?

ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."

How do I buy shares of ProPhase Labs?

Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ProPhase Labs' stock price today?

One share of PRPH stock can currently be purchased for approximately $7.24.

How big of a company is ProPhase Labs?

ProPhase Labs has a market capitalization of $84.01 million and generates $9.88 million in revenue each year. ProPhase Labs employs 48 workers across the globe.

What is ProPhase Labs' official website?

The official website for ProPhase Labs is www.prophaselabs.com.

How can I contact ProPhase Labs?

ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.